Comparison of Maternal and Fetal Plasma X Box Binding Protein 1 Levels Between Pregnancies With Fetal Growth Retardation and Healthy Controls

IF 2.5 3区医学 Q3 IMMUNOLOGY

American Journal of Reproductive Immunology Pub Date : 2025-05-08 DOI:10.1111/aji.70094

Sena Ünlü, Nizamettin Bozbay, Fikret Akyürek, Gökcen Örgül, Çetin Çelik

{"title":"Comparison of Maternal and Fetal Plasma X Box Binding Protein 1 Levels Between Pregnancies With Fetal Growth Retardation and Healthy Controls","authors":"Sena Ünlü, Nizamettin Bozbay, Fikret Akyürek, Gökcen Örgül, Çetin Çelik","doi":"10.1111/aji.70094","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>This study aimed to compare maternal and cord serum X box binding protein 1 (XBP-1) levels in pregnant women with fetal growth restriction (FGR) with healthy pregnancies.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>This prospective case-control study was conducted between January 1, 2022, and May 31, 2022, at the Gynecology and Obstetrics Clinic of Selçuk University Faculty of Medicine Hospital. Forty-three pregnant women and fetuses with isolated FGR with abdominal circumference (AC) or estimated fetal weight (EFW) below the 10th percentile according to ultrasonographic measurements constituted the study group; 43 healthy pregnant women and fetuses constituted the control group. Serum XBP-1 levels in prenatal maternal and cord blood were measured by ELISA and compared between the two groups.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The mean maternal blood XBP-1 level was 1910.22 ± 607.07 ng/L in the FGR group and 1638.89 ± 385.80 ng/L in the control group (<i>p</i> = 0.044). Cord blood XBP-1 levels were 1837.72 ± 942.67 and 1346.14 ± 664.09 ng/L in the study and control groups, respectively (<i>p</i> = 0.006). Maternal XBP-1 levels were found to discriminate FGR with a sensitivity of 80% and specificity of 60% at a value of 1405 ng/L. For cord blood XBP-1, 869.2 ng/L was the best cut-off, with 98% sensitivity and 67% specificity. In ROC analysis, the area under the curve was found to be 0.626 and 0.671, and <i>p</i> values were found to be 0.044 and 0.006 for maternal serum XBP-1 and cord blood XBP-1, respectively.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>In the study, serum XBP-1 levels in both maternal and fetal umbilical cord blood were found to be higher in patients with FGR. Considering the role of XBP-1 in metabolic pathways and cellular functions, XBP-1 may have an important role in the pathophysiology of FGR.</p>\n </section>\n </div>","PeriodicalId":7665,"journal":{"name":"American Journal of Reproductive Immunology","volume":"93 5","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Reproductive Immunology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/aji.70094","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

This study aimed to compare maternal and cord serum X box binding protein 1 (XBP-1) levels in pregnant women with fetal growth restriction (FGR) with healthy pregnancies.

Materials and Methods

This prospective case-control study was conducted between January 1, 2022, and May 31, 2022, at the Gynecology and Obstetrics Clinic of Selçuk University Faculty of Medicine Hospital. Forty-three pregnant women and fetuses with isolated FGR with abdominal circumference (AC) or estimated fetal weight (EFW) below the 10th percentile according to ultrasonographic measurements constituted the study group; 43 healthy pregnant women and fetuses constituted the control group. Serum XBP-1 levels in prenatal maternal and cord blood were measured by ELISA and compared between the two groups.

Results

The mean maternal blood XBP-1 level was 1910.22 ± 607.07 ng/L in the FGR group and 1638.89 ± 385.80 ng/L in the control group (p = 0.044). Cord blood XBP-1 levels were 1837.72 ± 942.67 and 1346.14 ± 664.09 ng/L in the study and control groups, respectively (p = 0.006). Maternal XBP-1 levels were found to discriminate FGR with a sensitivity of 80% and specificity of 60% at a value of 1405 ng/L. For cord blood XBP-1, 869.2 ng/L was the best cut-off, with 98% sensitivity and 67% specificity. In ROC analysis, the area under the curve was found to be 0.626 and 0.671, and p values were found to be 0.044 and 0.006 for maternal serum XBP-1 and cord blood XBP-1, respectively.

Conclusions

In the study, serum XBP-1 levels in both maternal and fetal umbilical cord blood were found to be higher in patients with FGR. Considering the role of XBP-1 in metabolic pathways and cellular functions, XBP-1 may have an important role in the pathophysiology of FGR.

查看原文本刊更多论文

发育迟缓孕妇与健康孕妇血浆X盒结合蛋白1水平的比较

目的比较胎儿生长受限（FGR）孕妇与正常妊娠孕妇血清X盒结合蛋白1 （XBP-1）水平。材料和方法本前瞻性病例对照研究于2022年1月1日至2022年5月31日在sel鲁克大学医学院附属医院妇产科诊所进行。43例腹部围（AC）或估计胎儿体重（EFW）低于超声测量第10百分位的孤立性FGR孕妇和胎儿组成研究组；健康孕妇及胎儿43例作为对照组。采用酶联免疫吸附试验（ELISA）检测两组患者产前母体血和脐带血血清XBP-1水平，并进行比较。结果FGR组产妇血中XBP-1水平为1910.22±607.07 ng/L，对照组为1638.89±385.80 ng/L （p = 0.044）。研究组和对照组脐带血XBP-1水平分别为1837.72±942.67、1346.14±664.09 ng/L （p = 0.006）。在1405 ng/L时，母体XBP-1水平对FGR的鉴别灵敏度为80%，特异性为60%。脐带血XBP-1的最佳临界值为869.2 ng/L，敏感性98%，特异性67%。在ROC分析中，母体血清XBP-1和脐带血XBP-1的曲线下面积分别为0.626和0.671，p值分别为0.044和0.006。结论本研究发现FGR患者血清XBP-1和胎儿脐带血XBP-1水平均较高。考虑到XBP-1在代谢途径和细胞功能中的作用，XBP-1可能在FGR的病理生理中发挥重要作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Reproductive Immunology 医学-免疫学

CiteScore

6.20

自引率

5.60%

发文量

314

审稿时长

2 months

期刊介绍： The American Journal of Reproductive Immunology is an international journal devoted to the presentation of current information in all areas relating to Reproductive Immunology. The journal is directed toward both the basic scientist and the clinician, covering the whole process of reproduction as affected by immunological processes. The journal covers a variety of subspecialty topics, including fertility immunology, pregnancy immunology, immunogenetics, mucosal immunology, immunocontraception, endometriosis, abortion, tumor immunology of the reproductive tract, autoantibodies, infectious disease of the reproductive tract, and technical news.